12/23/2025
A new option for the treatment of obesity is now FDA approved! More options and easier route (pill vs injection) is great to be able to offer patients!
Here are some thoughts from us:
- The approval is for oral Semaglutide for weight loss. 💊 So this is not a new medication, but it is in pill form at a much higher dose than what was available in oral Semaglutide for diabetics (Rybelsus). At lower doses, like in Rybelsus, oral Semaglutide did not lead to significant weight loss, so it has not been used widely for this.
- This new oral Semaglutide was tested at dosages up to 10X the maximum injectable dose. This is because oral medication’s need to go through the liver, which clears out much of the active drug before it can do what it’s supposed to do - thus requiring higher dosages.
- Weight loss potential in clinical trials looked good at 16% but it took longer than via injection – 64 weeks in clinical trials.
- It looks like the medication should be available in it’s starting dosages in January. Price and insurance coverage to be determined.
Overall, this is an exciting advancement and obesity medication, and one that will be watching closely and offering to our clients once available!
Let me know your questions in the comments!

The U.S. Food and Drug Administration approved Novo Nordisk's weight-loss pill on Monday, giving the Danish drugmaker a leg up in the race to market a potent oral medication for shedding pounds as it looks to regain lost ground from rival Eli Lilly .
